Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) is progressing with a pivotal trial for Alzheimer’s disease, with topline data expected in Q4 2021. Chris Lowe, the COO and CFO, is scheduled to participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on May 11, 2021, at 3:30 p.m. EDT. This event will be accessible via the Investor Calendar on Cortexyme’s website and archived for 90 days. Cortexyme focuses on innovative therapeutics targeting neurodegenerative diseases, specifically advancing its candidate, atuzaginstat (COR388), through the ongoing GAIN Trial.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event, on Tuesday, May 11, 2021, at 3:30 p.m. EDT (12:30 p.m. PDT).

A live webcast of the fireside chat will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005295/en/

FAQ

What is Cortexyme's lead therapeutic candidate in development?

Cortexyme's lead therapeutic candidate is atuzaginstat (COR388), which is currently in the ongoing GAIN Trial for Alzheimer’s disease.

When will Cortexyme present at the BofA Securities Healthcare Conference?

Cortexyme will participate in the BofA Securities 2021 Healthcare Conference on May 11, 2021, at 3:30 p.m. EDT.

Where can I access the live webcast of Cortexyme’s fireside chat?

The live webcast of Cortexyme’s fireside chat can be accessed on the Investor Calendar page of their investor website at ir.cortexyme.com.

What is the significance of the GAIN Trial for Cortexyme?

The GAIN Trial is a pivotal Phase 2/3 clinical trial for Cortexyme's lead candidate targeting Alzheimer’s disease, with important topline data expected in Q4 2021.

How long will the webcast of the Cortexyme fireside chat be available?

The webcast will be archived on Cortexyme's website for 90 days after the event.